A Phase 3 clinical trial involving cagrilintide was registered on September 14, 2026. The study, titled "Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema," is listed under identifier NCT07817251.
According to the registration, the trial is designed to examine tolerability in people with type 2 diabetes who switch from semaglutide to CagriSema, a combination product containing cagrilintide. The trial status is currently listed as not yet recruiting.
Cagrilintide remains classified as an unapproved compound under research investigation. No results, efficacy data, or safety outcomes have been posted for this trial at this stage. The current record reflects only the trial's registration status, phase, and stated purpose as described in the public listing.
Further details, including recruitment timelines and study design, are expected to be updated as the trial progresses through the clinicaltrials.gov registry. Readers interested in this compound can consult the compound overview for additional background and context.